TABLE 4.
Cox proportional hazards regression models for renal failurea
| Variable | Final model |
Alternative model 1 |
Alternative model 2 |
Alternative model 3 |
||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| Treatment with another nephrotoxic drugb | 2.50 (1.02–6.14) | 0.046 | 2.50 (1.01–6.22) | 0.048 | 2.31 (0.95–5.65) | 0.065 | 2.47 (0.99–6.19) | 0.053 |
| Treatment with a vasoactive drug | 2.75 (1.17–6.43) | 0.020 | 2.75 (1.17–6.44) | 0.020 | 2.82 (1.20–6.63) | 0.018 | 1.78 (1.18–6.57) | 0.019 |
| Baseline creatinine clearance (ml/min) | 1.01 (1.00–1.01) | 0.035 | 1.01 (1.00–1.01) | 0.035 | 1.01 (1.00–1.01) | 0.030 | 1.01 (1.00–1.01) | 0.034 |
| PMB dose (mg/kg/day) | 0. 78 (0.49–1.27) | 0.324 | 0.78 (0.43–1.41) | 0.422 | — | — | — | — |
| Total daily dose (mg) | — | — | — | — | 1.00 (0.99–1.01) | 0.986 | 0.99 (0.99–1.01) | 0.792 |
| Wt (kg) | — | — | 1.00 (0.98–1.02) | 0.999 | — | — | 1.01 (0.98–1.03) | 0.485 |
PMB, polymyxin B; HR, hazard ratio; CI, confidence interval; —, not included or not performed.
Vancomycin, aminoglycosides, and amphotericin B.